Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Abdel-Rahman

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Genes|January 23, 2024
<i>SLCO1B1</i> Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric HypercholesterolemiaJonathan B Wagner, Susan Abdel-Rahman, Geetha Raghuveer, et al.
The AAPS Journal|March 10, 2026
PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation DevelopmentGilbert J Burckart, Susan Abdel-Rahman, Caleb Choi, et al.
Journal of Pharmaceutical Sciences|June 20, 2026
Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needsSydney Stern, Yifei Zhang, Michelle Pressly, et al.
Contemporary Clinical Trials|March 5, 2025
Development of a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders: Study protocol for the naltrexone neuroimaging randomized controlled trial (NN-RCT)Stephani L Stancil, Mariah E Brewe, John Tumberger, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Genes|January 23, 2024
<i>SLCO1B1</i> Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric HypercholesterolemiaJonathan B Wagner, Susan Abdel-Rahman, Geetha Raghuveer, et al.
The AAPS Journal|March 10, 2026
PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation DevelopmentGilbert J Burckart, Susan Abdel-Rahman, Caleb Choi, et al.
Journal of Pharmaceutical Sciences|June 20, 2026
Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needsSydney Stern, Yifei Zhang, Michelle Pressly, et al.
Contemporary Clinical Trials|March 5, 2025
Development of a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders: Study protocol for the naltrexone neuroimaging randomized controlled trial (NN-RCT)Stephani L Stancil, Mariah E Brewe, John Tumberger, et al.
Pageof 4